aaiPharma Inc., of Wilmington, N.C., appointed David Silver senior vice president of strategic marketing, analytics and planning, and Gina Gutzeit interim executive vice president and chief financial officer.
Acologix Inc., of Emeryville, Calif., appointed Dale Stringfellow to its board.
Antigenics Inc., of New York, appointed Peter Thornton chief financial officer and senior vice president.
Bionomics, of Adelaide, Australia, appointed Tim Harris to its scientific advisory board and Kerstin Holata director of drug discovery.
BioSource International Inc., of Camarillo, Calif., named Alan Edrick executive vice president and chief financial officer.
The Biotechnology Council of New Jersey in Trenton, N.J., elected Kenneth Moch, CEO of Parsippany, N.J.-based Alteon Inc., its chairman.
BioVeris Corp., of Gaithersburg, Md., appointed John Quinn and William Crowley to its board.
Bodisen Biotech Inc., of Yang Ling, China, appointed David Gatton and Weirui Wan as independent board members.
Carrington Laboratories Inc., of Irving, Texas, appointed Ronald Banck and Edwin Meese to its board.
Celsion Corp., of Columbia, Md., appointed Anita Finkelstein vice president and general counsel, and David Braitman senior vice president of product development.
Genzyme Corp., of Cambridge, Mass., elected Gail Boudreaux to its board.
Halozyme Therapeutics Inc., of San Diego, named Kenneth Kelley to its board.
Inotek Pharmaceuticals Corp., of Beverly, Mass., appointed Jeffrey Walsh vice president of corporate development and commercial planning.
Inyx Inc., of New York, appointed Ulrich Bartke vice president of global sales and marketing.
IsoTis OrthoBiologics, of Lausanne, Switzerland, appointed Jean-Pierre Boucher to its board.
MetaMorphix Inc., of Savage, Md., elected Howard Minigh to its board.
MultiCell Technologies Inc., of Warwick, R.I., appointed Edward Maggio, Andrew Parkinson, Sangeeta Bhatia and Douglas Hixson to its scientific advisory board.
NovaDel Pharma Inc., of Flemington, N.J., appointed Jean Whitehead Frydman vice president and general counsel.
Oncotech, of Tustin, Calif., appointed Michael Nobel to its board.
Optimer Pharmaceuticals Inc., of San Diego, formed a medical advisory board consisting of Sherwood Gorbach, Ellie Goldstein, Dale Gerding, David Ho and Shan-Chwen Chang.
Point Therapeutics Inc., of Boston, appointed Larry Pickering to its board.
Progenics Pharmaceuticals Inc., of Tarrytown, N.Y., reelected the following people to its board for one year: Paul Maddon as chairman and Ronald Prentki, Charles Baker, Kurt Briner, Mark Dalton, Stephen Goff, Paul Jacobson and David Scheinberg as directors.
ProtoKinetix Inc., of Vancouver, British Columbia, appointed Jean-Charles Quirion to its scientific advisory board.
Respironics Inc., of Murrysville, Pa., appointed Mylle Mangum to its board.
The San Jose Redevelopment Agency in San Jose, Calif., appointed the following people to its management team for the San Jose Bioscience Incubator and Innovation Center: Kathleen Imhoff, Melinda Richter, Kim Fisher and Mary Sidney.
Savient Pharmaceuticals Inc., of East Brunswick, N.J., appointed Philip Yachmetz senior vice president and general counsel.
Senomyx Inc., of La Jolla, Calif., appointed John Poyhonen chief financial and business officer.
Signet Laboratories Inc., of Dedham, Mass., appointed John Hallinan chief financial officer.
TransForm Pharmaceuticals Inc., of Lexington, Mass., named Paul Goldenheim president and a member of its board.
Valeant Pharmaceuticals Inc., of Costa Mesa, Calif., elected Elaine Ullian, Edward Burkhardt and Timothy Tyson to its board.
ViroPharma Inc., of Exton, Pa., appointed Colin Broom vice president and chief scientific officer.
Xencor Inc., of Monrovia, Calif., said its co-founder Stephen Mayo was elected to the National Academy of Sciences.